Corrigendum: Evaluation of Riboflavin Transporters as Targets for Drug Delivery and Theranostics

Front Pharmacol. 2020 Nov 26:11:617329. doi: 10.3389/fphar.2020.617329. eCollection 2020.

Lisa Bartmann^{1

2}, David Schumacher², Saskia von Stillfried³, Marieke Sternkopf², Setareh Alampour-Rajabi², Marc A M J van Zandvoort^{2

4}, Fabian Kiessling¹, Zhuojun Wu^{1

2}

¹ Institute for Experimental Molecular Imaging, University Clinic, RWTH Aachen University, Aachen, Germany.
² Institute for Molecular Cardiovascular Research, University Clinic, RWTH Aachen University, Aachen, Germany.
³ Institute of Pathology, University Clinic, RWTH Aachen University, Aachen, Germany.
⁴ Department of Genetics and Molecular Cell Biology, School for Cardiovascular Diseases (CARIM), School for Oncology and Developmental Biology (GROW), Maastricht University, Maastricht, Netherlands.

Abstract

[This corrects the article DOI: 10.3389/fphar.2019.00079.].

Keywords: RFVT; cancer therapy; nanocarrier; riboflavin; targeting molecules; theranostic.